Skip to main content

ESMO Congress 2023

27-10-2023 Colorectal Cancer News

PFS gain with sotorasib plus panitumumab in KRAS G12C-mutated CRC

CodeBreaK 300 data point to a significant progression-free survival advantage of sotorasib plus panitumumab versus standard care in the chemorefractory metastatic colorectal cancer setting.

Benefit of amivantamab combinations shown in various NSCLC populations

07-11-2023 NSCLC News

Three phase 3 trials have shown improved outcomes with amivantamab combinations in different populations of patients with advanced NSCLC.

INTERLACE data back induction chemotherapy for locally advanced cervical cancer

31-10-2023 Cervical Cancer News

Giving induction chemotherapy before chemoradiotherapy significantly boosts the survival of women with locally advanced cervical cancer.

Improved mCRPC outcomes with LuPSMA in phase 3 trial

30-10-2023 Prostate Cancer News

The PSMAfore trial of the radioligand LuPSMA has met its primary endpoint of a radiographic PFS benefit in men with metastatic metastatic castration-resistant prostate cancer.

Patients with HR-positive breast cancer benefit from datopotamab deruxtecan

27-10-2023 Breast Cancer News

Datopotamab deruxtecan improves the outcomes of pretreated patients with HR-positive, HER2-negative metastatic breast cancer.

Expert Interviews and Insights

Panel discussion: Recent advances in early and advanced stage non-small-cell lung cancer (NSCLC) presented at ESMO 2023

NSCLC Panel Discussion

Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2.

Supported by:
  • F. Hoffmann-La Roche Ltd.

ESMO23: Small-cell lung cancer highlights

SCLC Expert Interview

Dr. Luis Paz-Ares and Andrea Ardizzoni discuss the top small-cell lung cancer abstracts presented at ESMO 2023.

Supported by:
  • F. Hoffmann-La Roche Ltd.

Cancer of Unknown Primary: Key results from ESMO 2023

ESMO 2023 gave researchers the opportunity to highlight advances in the molecular diagnosis and treatment for cancer of unknown primary.

Watch our video interviews to find out more about the latest developments for patients with this rare diagnosis.

Supported by:
  • F. Hoffmann-La Roche Ltd.

ESMO 2023: A new option for thyroid cancer

Thyroid Cancer Expert Interview

Dr. Laura Locati comments on the LIBRETTO-531 study of selpercatinib in previously untreated RET-mutant medullary thyroid carcinoma, which has provided a new treatment option for this patient population.

ESMO 2023: Advances in urothelial cancer

Urothelial Cancer Expert Interview

Dr. Enrique Grande discusses the findings of the EV-302 trial of enfortumab vedotin plus pembrolizumab and the CheckMate 901 trial of nivolumab plus chemotherapy, both conducted in the advanced urothelial cancer setting.

ESMO 2023: Hot topics in gynecologic cancer

Gynecologic Cancer Expert Interview

Dr. Domenica Lorusso takes us through the key gynecologic cancer studies presented at the conference, including the KEYNOTE-A18 and innovaTV 301 trials in cervical cancer and DUO-E in endometrial cancer.

25-10-2023 Cervical Cancer News

Tisotumab vedotin improves recurrent and metastatic cervical cancer survival

Tisotumab vedotin could be an option for women with recurrent or metastatic cervical cancer who progress on first-line doublet chemotherapy.

Adjuvant alectinib ‘new treatment strategy’ for ALK-positive NSCLC

23-10-2023 NSCLC News

Adjuvant treatment with alectinib confers a significant DFS benefit versus chemotherapy in resectable, ALK-positive non-small-cell lung cancer.

Durvalumab combinations boost PFS in advanced endometrial cancer

22-10-2023 Endometrial Cancer News

Durvalumab plus chemotherapy followed by maintenance durvalumab with or without olaparib significantly improves the PFS of women with advanced endometrial cancer.

Tarlatamab shows promise for previously treated SCLC

21-10-2023 SCLC News

Tarlatamab has demonstrated durable antitumor activity and acceptable safety in previously treated patients with extensive-stage SCLC in the DeLLphi-301 trial.

Pembrolizumab addition benefits patients with HER2-positive gastric cancer

21-10-2023 Gastric Cancer News

People with advanced gastric or gastroesophageal junction cancer benefit from the addition of pembrolizumab to first-line trastuzumab plus chemotherapy.

24-10-2023 Urothelial Cancer News

EV-302 heralds practice change for advanced urothelial cancer

Combined treatment with enfortumab vedotin plus pembrolizumab has achieved an overall survival benefit in previously untreated advanced urothelial cancer.

Air pollution increases risk of breast cancer

26-10-2023 Breast Cancer News

Women who live and work in places with higher levels of particulate matter have a greater risk of developing breast cancer than women who live and work in less polluted areas.

Neoadjuvant cemiplimab in cutaneous squamous cell carcinoma

A recent phase II study shows encouraging results for the neoadjuvant treatment of cutaneous squamous cell carcinoma with the PD-1 inhibitor cemiplimab.

Added value for combination radium-223 and enzalutamide in mCRPC

26-10-2023 Prostate Cancer News

Combination treatment with radium-223 and enzalutamide appears to have added value for patients with metastatic castration-resistant prostate cancer in the REASSURE study.

Delays in European cancer care pathway and the role of AI

All countries need systematic reporting of diagnostic and therapeutic delays in cancer care, before AI can be adequately deployed to improve care. 

Unlock your free access to coverage of the ESMO Congress 2023

Precision medicine new standard in cancer of unknown primary?

CUPISCO trial results indicate extensive genomic profiling and molecularly guided therapy improve progression-free survival in patients with a cancer of unknown primary.

New immunotherapeutic approach for recurrent/refractory hematologic cancers

26-10-2023 Hematologic Cancer News

EVICTION study shows activation of γ9δ2 T cells by the monoclonal antibody ICT01 has the potential to become a novel immunotherapeutic approach for relapsing/refractory hematologic cancers.

NICHE-3: nivolumab plus relatlimab in dMMR colon cancer

26-10-2023 Colon Cancer News

NICHE-3 shows promising initial results for neoadjuvant nivolumab plus relatlimab in mismatch repair-deficient colon cancer.

Perioperative addition of nivolumab adds value in NSCLC

26-10-2023 NSCLC News

People with untreated resectable non-small-cell lung cancer benefit from the addition of nivolumab to neoadjuvant chemotherapy plus adjuvant treatment with nivolumab.

23-10-2023 Thyroid Cancer News

First-line selpercatinib supported for RET-mutant medullary thyroid cancer

LIBRETTO-531 data establish selpercatinib as the standard of care for first-line treatment of advanced RET-mutant medullary thyroid cancer.

Stay up to date with more from Springer Medicine

Biomarker-driven management of NSCLC (Link opens in a new window)


Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

1.0 AMA PRA Category 1 Credit(s)™

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.

Precision medicine advances in thyroid cancer: Translating clinical evidence into practice (Link opens in a new window)

Thyroid Cancer Independent Medical Education

Identifying molecular biomarkers is crucial in determining the best targeted treatment options for your patients with advanced thyroid cancer.

Join our expert-led multi-format educational program that explores the continuing discovery of new genomic targets and delivers the latest research in molecular testing and the application of targeted therapies for thyroid cancer.

Start by watching our webcast and short vodcasts.

Supported by:
  • Lilly

Episode 5: Next-generation sequencing in cancer

Biomarkers Podcast

Professor Andrew Beggs discusses best practice in the use of next-generational sequencing within thyroid and non-small cell lung cancers.

Listen now »

Prof. Andrew Beggs